Trial Profile
Phase Ib/IIa study of AV4025, an HCV NS5A Inhibitor in HCV-infected patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Apr 2016
Price :
$35
*
At a glance
- Drugs AV 4025 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 11 Apr 2016 New trial record